The Stomach Cancer Treatment Market size was estimated USD 4.3 billion in 2022 and is expected to reach USD 11.47 billion By 2030 at a CAGR of 13% during the forecast period of 2023-2030.
The fifth most frequent kind of cancer worldwide and one of the main causes of cancer-related fatalities is gastric cancer. In 2020, over 1.1 million new instances of the disease were reported globally, according to Globocan. During the projection period, it is projected that the rising disease burden and the approval of pipeline candidates will drive the market's expansion. Risk factors for stomach cancer include alterations in lifestyle, such as smoking and drunkenness, an increase in obesity, and a rise in gastroesophageal reflux syndrome. Asia Pacific and Europe have the highest disease incidence rates, respectively.
In industrialised nations like the U.S., targeted medications like Herceptin and Cyramza are routinely used to treat gastric cancer, whereas chemotherapy is still the go-to treatment in developing nations like China and India. Few medications have been licenced for treating the disease's severe metastatic stages. The treatment of advanced metastatic stages of the illness is anticipated to change with the introduction of PD-1 inhibitors like Opdivo and Keytruda. The approval of novel immunotherapy and targeted medications predicted to boost market expansion during the course of the forecast.
DRIVERS
Advances in Treatment Modalities and an Increasing Incidence of Stomach. Cancer
The use of minimally invasive procedures is expanding due to government initiatives and funding.
One important market driver is the increased incidence of stomach cancer around the world. The ageing of the population, dietary habits, and lifestyle changes all play a role in the rising prevalence of stomach cancer. Treatment outcomes for patients with stomach cancer have improved as a result of the introduction of novel and targeted medicines, such as immunotherapies, precision medicine, and combination therapy. These developments encourage market expansion since they provide improved efficacy and fewer adverse effects. The development of the market is significantly influenced by government programmes that raise cancer awareness, early detection programmes, and financing for research and development of treatments for stomach cancer.
RESTRAIN
Limited Early Detection and Awareness and High Treatment Costs.
Negative Treatment Effects.
OPPORTUNITY
Emerging Markets, Personalised Medicine.
Opportunities for more precise and successful stomach cancer therapies are presented by the growing emphasis on personalised medicine, which is based on patients' genetic profiles and tumour features. Untapped markets in developing nations offer big chances for market participants to grow their presence and offer affordable treatment alternatives to more people.
CHALLENGES
Barriers to regulation and drug resistance.
Armed conflicts and wars have the potential to seriously damage the infrastructure supporting the healthcare industry, including hospitals, clinics, and research institutions. For patients in the impacted areas, this disruption might make it more difficult to find and receive treatment options for stomach cancer. Supply-Chain Breakdowns The battle may interfere with the flow of drugs, medical supplies, and other vital materials required for treating stomach cancer. This can affect patient care by causing shortages and higher prices for these products. Limited Access to Medical Expertise Ongoing wars may force healthcare workers to relocate, leaving afflicted communities with little access to specialised medical knowledge for the treatment of stomach cancer. Redirection of Funding Governments may divert cash and resources from healthcare to defence and security during times of war, thus lowering investments in the healthcare sector, including cancer therapy.
IMPACT OF ONGOING RECESSION
Lower Healthcare Costs Individuals and families may experience financial difficulties during a recession, which could result in lower healthcare spending overall. To conserve money, patients may decide to put off or skip non-urgent medical procedures, such as stomach cancer screenings and treatments. Delays in Diagnosis Economic uncertainty and financial constraints may cause stomach cancer diagnoses to be delayed because patients may be reluctant to seek immediate medical assistance. When cancer is discovered later on due to a delayed diagnosis, it may already be in a more advanced stage, which could alter how well it responds to therapy. Effect on Healthcare Professionals During a recession, healthcare providers, including hospitals and clinics, may face financial difficulties. Healthcare facilities may be under pressure, which could impair their capacity to deliver high-quality care. These pressures include decreased patient volumes, postponed payments, and rising prices for medical supplies and equipment. belly cancer Treatment for stomach cancer can be expensive, particularly with the development of cutting-edge medicines and specialised medications. Patients may have trouble affording these pricey treatments during a recession, which could reduce their treatment options and reduce their effectiveness. Clinical research and trials: The financing for clinical trials and research into stomach cancer may be impacted by budget cuts brought on by the recession. New therapeutic choices and cutting-edge remedies may not be available as soon as planned due to slower research and development progress.
By Treatment Type
Immunotherapy
Targeted Therapy
Chemotherapy
Radiation Therapy and Surgery
By Disease Indication
Gastric Cancer/Gastroesophageal Junction Cancer
Gastrointestinal Stromal Tumors
Route of Administration
Oral
Injectable
By Drug Class
PD-1/PD-L1 Inhibitors
HER2 Antagonists
VEGFR2 Antagonists
Others
By Distribution Channel
Hospital Pharmacies
Specialty & Retail Pharmacies
Others
.png)
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
REGIONAL ANALYSES
With a revenue share of more than 55.04%, Asia Pacific commanded the gastric cancer therapy market in 2021. This is mostly brought on by the greater incidence of stomach cancer in this area. Around 139,000 new cases were reported in Japan in 2020, whereas 480,000 were reported in China. Chemotherapy is the most popular treatment choice in nations like China, but the presence of a robust product pipeline and the anticipated approval of the treatments will support regional growth throughout the forecast period.
Due to rising investments in the creation of cutting-edge treatment alternatives and an increasing target patient population, Europe is anticipated to experience significant growth over the course of the projected period.
The major key players are Novartis AG, Pfizer, Inc., Mylan N.V., F. Hoffmann La Roche Ltd, Eli Lilly And Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Samsung Bioepis, Bristol Myers Squibb Company and others.
Bold Therapeutics: In May 2021, For its bold-100, a ruthenium-based small molecule therapy that is a first in class, Bold Therapeutics was awarded the orphan Drug Designation (ODD).
Bristol Myers Squibb: In April 2021,The first immunotherapy for the first-line treatment of gastric cancer, opdivo (nivolumab), was approved by the US FDA for Bristol Myers Squibb.
| Report Attributes | Details |
| Market Size in 2022 | US$ 4.3 Bn |
| Market Size by 2030 | US$ 11.47 Bn |
| CAGR | CAGR of 13% From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2020-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Treatment (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery) • By Disease Indication (Gastric Cancer/Gastroesophageal Junction Cancer, Gastrointestinal Stromal Tumors, Route of Administration, Oral, Injectable) • By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others) • By Distribution Channel (Hospital Pharmacies, Specialty & Retail Pharmacies, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Novartis AG, Pfizer, Inc., Mylan N.V., F. Hoffmann La Roche Ltd, Eli Lilly And Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Samsung Bioepis, Bristol Myers Squibb Company |
| Key Drivers | • Advances in Treatment Modalities and an Increasing Incidence of Stomach. Cancer • The use of minimally invasive procedures is expanding due to government initiatives and funding. |
| Market Restraints | • Limited Early Detection and Awareness and High Treatment Costs. • Negative Treatment Effects. |
Ans: The Stomach Cancer Treatment Market is expected to grow at 13.0% CAGR from 2023 to 2030.
Ans: According to our analysis, the Stomach Cancer Treatment Market is anticipated to reach USD 11.47 billion By 2030.
Ans: The leading participants in the stomach cancer treatment are Novartis AG, Pfizer, Inc., Mylan N.V., F. Hoffmann La Roche Ltd, Eli Lilly And Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd.
Ans: The introduction and widespread use of targeted and immunotherapy medications for the treatment of stomach cancer are the main factors propelling market expansion.
Ans: Yes, you may request customization based on your company's needs.
TABLE OF CONTENT
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of Ukraine- Russia War
4.2 Impact of Recession
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Stomach Cancer Treatment Market, By Treatment Type
8.1 Immunotherapy
8.2 Targeted Therapy
8.3 Chemotherapy
8.4 Radiation Therapy and Surgery
9. Stomach Cancer Treatment Market, By Disease Indication
9.1 Gastric Cancer/Gastroesophageal Junction Cancer
9.2 Gastrointestinal Stromal Tumors
9.3 Route of Administration
9.4 Oral
9.5 Injectable
10. Stomach Cancer Treatment Market, By Drug Class
10.1 PD-1/PD-L1 Inhibitors
10.2 HER2 Antagonists
10.3 VEGFR2 Antagonists
10.4 Others
11. Stomach Cancer Treatment Market, By Distribution Channel
11.1 Hospital Pharmacie
11.2 Specialty & Retail Pharmacies
11.3 Others
12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 North America Stomach Cancer Treatment Market by Country
12.2.2North America Stomach Cancer Treatment Market by Treatment Type
12.2.3 North America Stomach Cancer Treatment Market By Disease Indication
12.2.4 North America Stomach Cancer Treatment Market By Drug Class
12.2.5 North America Stomach Cancer Treatment Market By Distribution Channel
12.2.6 USA
12.2.6.1 USA Stomach Cancer Treatment Market by Treatment Type
12.2.6.2 USA Stomach Cancer Treatment Market By Disease Indication
12.2.6.3 USA Stomach Cancer Treatment Market By Drug Class
12.2.6.4 USA Stomach Cancer Treatment Market By Distribution Channel
12.2.7 Canada
12.2.7.1 Canada Stomach Cancer Treatment Market by Treatment Type
12.2.7.2 Canada Stomach Cancer Treatment Market By Disease Indication
12.2.7.3 Canada Stomach Cancer Treatment Market By Drug Class
12.2.7.4 Canada Stomach Cancer Treatment Market By Distribution Channel
12.2.8 Mexico
12.2.8.1 Mexico Stomach Cancer Treatment Market by Treatment Type
12.2.8.2 Mexico Stomach Cancer Treatment Market By Disease Indication
12.2.8.3 Mexico Stomach Cancer Treatment Market By Drug Class
12.2.8.4 Mexico Stomach Cancer Treatment Market By Distribution Channel
12.3 Europe
12.3.1 Eastern Europe
12.3.1.1 Eastern Europe Stomach Cancer Treatment Market by Country
12.3.1.2 Eastern Europe Stomach Cancer Treatment Market by Treatment Type
12.3.1.3 Eastern Europe Stomach Cancer Treatment Market By Disease Indication
12.3.1.4 Eastern Europe Stomach Cancer Treatment Market By Drug Class
12.3.1.5 Eastern Europe Stomach Cancer Treatment Market By Distribution Channel
12.3.1.6 Poland
12.3.1.6.1 Poland Stomach Cancer Treatment Market by Treatment Type
12.3.1.6.2 Poland Stomach Cancer Treatment Market By Disease Indication
12.3.1.6.3 Poland Stomach Cancer Treatment Market By Drug Class
12.3.1.6.4 Poland Stomach Cancer Treatment Market By Distribution Channel
12.3.1.7 Romania
12.3.1.7.1 Romania Stomach Cancer Treatment Market by Treatment Type
12.3.1.7.2 Romania Stomach Cancer Treatment Market By Disease Indication
12.3.1.7.3 Romania Stomach Cancer Treatment Market By Drug Class
12.3.1.7.4 Romania Stomach Cancer Treatment Market By Distribution Channel
12.3.1.8 Hungary
12.3.1.8.1 Hungary Stomach Cancer Treatment Market by Treatment Type
12.3.1.8.2 Hungary Stomach Cancer Treatment Market By Disease Indication
12.3.1.8.3 Hungary Stomach Cancer Treatment Market By Drug Class
12.3.1.8.4 Hungary Stomach Cancer Treatment Market By Distribution Channel
12.3.1.9 Turkey
12.3.1.9.1 Turkey Stomach Cancer Treatment Market by Treatment Type
12.3.1.9.2 Turkey Stomach Cancer Treatment Market By Disease Indication
12.3.1.9.3 Turkey Stomach Cancer Treatment Market By Drug Class
12.3.1.9.4 Turkey Stomach Cancer Treatment Market By Distribution Channel
12.3.1.10 Rest of Eastern Europe
12.3.1.10.1 Rest of Eastern Europe Stomach Cancer Treatment Market by Treatment Type
12.3.1.10.2 Rest of Eastern Europe Stomach Cancer Treatment Market By Disease Indication
12.3.1.10.3 Rest of Eastern Europe Stomach Cancer Treatment Market By Drug Class
12.3.1.10.4 Rest of Eastern Europe Stomach Cancer Treatment Market By Distribution Channel
12.3.2 Western Europe
12.3.2.1 Western Europe Stomach Cancer Treatment Market by Country
12.3.2.2 Western Europe Stomach Cancer Treatment Market by Treatment Type
12.3.2.3 Western Europe Stomach Cancer Treatment Market By Disease Indication
12.3.2.4 Western Europe Stomach Cancer Treatment Market By Drug Class
12.3.2.5 Western Europe Stomach Cancer Treatment Market By Distribution Channel
12.3.2.6 Germany
12.3.2.6.1 Germany Stomach Cancer Treatment Market by Treatment Type
12.3.2.6.2 Germany Stomach Cancer Treatment Market By Disease Indication
12.3.2.6.3 Germany Stomach Cancer Treatment Market By Drug Class
12.3.2.6.4 Germany Stomach Cancer Treatment Market By Distribution Channel
12.3.2.7 France
12.3.2.7.1 France Stomach Cancer Treatment Market by Treatment Type
12.3.2.7.2 France Stomach Cancer Treatment Market By Disease Indication
12.3.2.7.3 France Stomach Cancer Treatment Market By Drug Class
12.3.2.7.4 France Stomach Cancer Treatment Market By Distribution Channel
12.3.2.8 UK
12.3.2.8.1 UK Stomach Cancer Treatment Market by Treatment Type
12.3.2.8.2 UK Stomach Cancer Treatment Market By Disease Indication
12.3.2.8.3 UK Stomach Cancer Treatment Market By Drug Class
12.3.2.8.4 UK Stomach Cancer Treatment Market By Distribution Channel
12.3.2.9 Italy
12.3.2.9.1 Italy Stomach Cancer Treatment Market by Treatment Type
12.3.2.9.2 Italy Stomach Cancer Treatment Market By Disease Indication
12.3.2.9.3 Italy Stomach Cancer Treatment Market By Drug Class
12.3.2.9.4 Italy Stomach Cancer Treatment Market By Distribution Channel
12.3.2.10 Spain
12.3.2.10.1 Spain Stomach Cancer Treatment Market by Treatment Type
12.3.2.10.2 Spain Stomach Cancer Treatment Market By Disease Indication
12.3.2.10.3 Spain Stomach Cancer Treatment Market By Drug Class
12.3.2.10.4 Spain Stomach Cancer Treatment Market By Distribution Channel
12.3.2.11 Netherlands
12.3.2.11.1 Netherlands Stomach Cancer Treatment Market by Treatment Type
12.3.2.11.2 Netherlands Stomach Cancer Treatment Market By Disease Indication
12.3.2.11.3 Netherlands Stomach Cancer Treatment Market By Drug Class
12.3.2.11.4 Netherlands Stomach Cancer Treatment Market By Distribution Channel
12.3.2.12 Switzerland
12.3.2.12.1 Switzerland Stomach Cancer Treatment Market by Treatment Type
12.3.2.12.2 Switzerland Stomach Cancer Treatment Market By Disease Indication
12.3.2.12.3 Switzerland Stomach Cancer Treatment Market By Drug Class
12.3.2.12.4 Switzerland Stomach Cancer Treatment Market By Distribution Channel
12.3.2.13 Austria
12.3.2.13.1 Austria Stomach Cancer Treatment Market by Treatment Type
12.3.2.13.2 Austria Stomach Cancer Treatment Market By Disease Indication
12.3.2.13.3 Austria Stomach Cancer Treatment Market By Drug Class
12.3.2.13.4 Austria Stomach Cancer Treatment Market By Distribution Channel
12.3.2.14 Rest of Western Europe
12.3.2.14.1 Rest of Western Europe Stomach Cancer Treatment Market by Treatment Type
12.3.2.14.2 Rest of Western Europe Stomach Cancer Treatment Market By Disease Indication
12.3.2.14.3 Rest of Western Europe Stomach Cancer Treatment Market By Drug Class
12.3.2.14.4 Rest of Western Europe Stomach Cancer Treatment Market By Distribution Channel
12.4 Asia-Pacific
12.4.1 Asia Pacific Stomach Cancer Treatment Market by Country
12.4.2 Asia Pacific Stomach Cancer Treatment Market by Treatment Type
12.4.3 Asia Pacific Stomach Cancer Treatment Market By Disease Indication
12.4.4 Asia Pacific Stomach Cancer Treatment Market By Drug Class
12.4.5 Asia Pacific Stomach Cancer Treatment Market By Distribution Channel
12.4.6 China
12.4.6.1 China Stomach Cancer Treatment Market by Treatment Type
12.4.6.2 China Stomach Cancer Treatment Market By Disease Indication
12.4.6.3 China Stomach Cancer Treatment Market By Drug Class
12.4.6.4 China Stomach Cancer Treatment Market By Distribution Channel
12.4.7 India
12.4.7.1 India Stomach Cancer Treatment Market by Treatment Type
12.4.7.2 India Stomach Cancer Treatment Market By Disease Indication
12.4.7.3 India Stomach Cancer Treatment Market By Drug Class
12.4.7.4 India Stomach Cancer Treatment Market By Distribution Channel
12.4.8 Japan
12.4.8.1 Japan Stomach Cancer Treatment Market by Treatment Type
12.4.8.2 Japan Stomach Cancer Treatment Market By Disease Indication
12.4.8.3 Japan Stomach Cancer Treatment Market By Drug Class
12.4.8.4 Japan Stomach Cancer Treatment Market By Distribution Channel
12.4.9 South Korea
12.4.9.1 South Korea Stomach Cancer Treatment Market by Treatment Type
12.4.9.2 South Korea Stomach Cancer Treatment Market By Disease Indication
12.4.9.3 South Korea Stomach Cancer Treatment Market By Drug Class
12.4.9.4 South Korea Stomach Cancer Treatment Market By Distribution Channel
12.4.10 Vietnam
12.4.10.1 Vietnam Stomach Cancer Treatment Market by Treatment Type
12.4.10.2 Vietnam Stomach Cancer Treatment Market By Disease Indication
12.4.10.3 Vietnam Stomach Cancer Treatment Market By Drug Class
12.4.10.4 Vietnam Stomach Cancer Treatment Market By Distribution Channel
12.4.11 Singapore
12.4.11.1 Singapore Stomach Cancer Treatment Market by Treatment Type
12.4.11.2 Singapore Stomach Cancer Treatment Market By Disease Indication
12.4.11.3 Singapore Stomach Cancer Treatment Market By Drug Class
12.4.11.4 Singapore Stomach Cancer Treatment Market By Distribution Channel
12.4.12 Australia
12.4.12.1 Australia Stomach Cancer Treatment Market by Treatment Type
12.4.12.2 Australia Stomach Cancer Treatment Market By Disease Indication
12.4.12.3 Australia Stomach Cancer Treatment Market By Drug Class
12.4.12.4 Australia Stomach Cancer Treatment Market By Distribution Channel
12.4.13 Rest of Asia-Pacific
12.4.13.1 Rest of Asia-Pacific Stomach Cancer Treatment Market by Treatment Type
12.4.13.2 Rest of Asia-Pacific Stomach Cancer Treatment Market By Disease Indication
12.4.13.3 Rest of Asia-Pacific Stomach Cancer Treatment Market By Drug Class
12.4.13.4 Rest of Asia-Pacific Stomach Cancer Treatment Market By Distribution Channel
12.5 Middle East & Africa
12.5.1 Middle East
12.5.1.1 Middle East Stomach Cancer Treatment Market by Country
12.5.1.2 Middle East Stomach Cancer Treatment Market by Treatment Type
12.5.1.3 Middle East Stomach Cancer Treatment Market By Disease Indication
12.5.1.4 Middle East Stomach Cancer Treatment Market By Drug Class
12.5.1.5 Middle East Stomach Cancer Treatment Market By Distribution Channel
12.5.1.6 UAE
12.5.1.6.1 UAE Stomach Cancer Treatment Market by Treatment Type
12.5.1.6.2 UAE Stomach Cancer Treatment Market By Disease Indication
12.5.1.6.3 UAE Stomach Cancer Treatment Market By Drug Class
12.5.1.6.4 UAE Stomach Cancer Treatment Market By Distribution Channel
12.5.1.7 Egypt
12.5.1.7.1 Egypt Stomach Cancer Treatment Market by Treatment Type
12.5.1.7.2 Egypt Stomach Cancer Treatment Market By Disease Indication
12.5.1.7.3 Egypt Stomach Cancer Treatment Market By Drug Class
12.5.1.7.4 Egypt Stomach Cancer Treatment Market By Distribution Channel
12.5.1.8 Saudi Arabia
12.5.1.8.1 Saudi Arabia Stomach Cancer Treatment Market by Treatment Type
12.5.1.8.2 Saudi Arabia Stomach Cancer Treatment Market By Disease Indication
12.5.1.8.3 Saudi Arabia Stomach Cancer Treatment Market By Drug Class
12.5.1.8.4 Saudi Arabia Stomach Cancer Treatment Market By Distribution Channel
12.5.1.9 Qatar
12.5.1.9.1 Qatar Stomach Cancer Treatment Market by Treatment Type
12.5.1.9.2 Qatar Stomach Cancer Treatment Market By Disease Indication
12.5.1.9.3 Qatar Stomach Cancer Treatment Market By Drug Class
12.5.1.9.4 Qatar Stomach Cancer Treatment Market By Distribution Channel
12.5.1.10 Rest of Middle East
12.5.1.10.1 Rest of Middle East Stomach Cancer Treatment Market by Treatment Type
12.5.1.10.2 Rest of Middle East Stomach Cancer Treatment Market By Disease Indication
12.5.1.10.3 Rest of Middle East Stomach Cancer Treatment Market By Drug Class
12.5.1.10.4 Rest of Middle East Stomach Cancer Treatment Market By Distribution Channel
12.5.2. Africa
12.5.2.1 Africa Stomach Cancer Treatment Market by Country
12.5.2.2 Africa Stomach Cancer Treatment Market by Treatment Type
12.5.2.3 Africa Stomach Cancer Treatment Market By Disease Indication
12.5.2.4 Africa Stomach Cancer Treatment Market By Drug Class
12.5.2.5 Africa Stomach Cancer Treatment Market By Distribution Channel
12.5.2.6 Nigeria
12.5.2.6.1 Nigeria Stomach Cancer Treatment Market by Treatment Type
12.5.2.6.2 Nigeria Stomach Cancer Treatment Market By Disease Indication
12.5.2.6.3 Nigeria Stomach Cancer Treatment Market By Drug Class
12.5.2.6.4 Nigeria Stomach Cancer Treatment Market By Distribution Channel
12.5.2.7 South Africa
12.5.2.7.1 South Africa Stomach Cancer Treatment Market by Treatment Type
12.5.2.7.2 South Africa Stomach Cancer Treatment Market By Disease Indication
12.5.2.7.3 South Africa Stomach Cancer Treatment Market By Drug Class
12.5.2.7.4 South Africa Stomach Cancer Treatment Market By Distribution Channel
12.5.2.8 Rest of Africa
12.5.2.8.1 Rest of Africa Stomach Cancer Treatment Market by Treatment Type
12.5.2.8.2 Rest of Africa Stomach Cancer Treatment Market By Disease Indication
12.5.2.8.3 Rest of Africa Stomach Cancer Treatment Market By Drug Class
12.5.2.8.4 Rest of Africa Stomach Cancer Treatment Market By Distribution Channel
12.6. Latin America
12.6.1 Latin America Stomach Cancer Treatment Market by Country
12.6.2 Latin America Stomach Cancer Treatment Market by Treatment Type
12.6.3 Latin America Stomach Cancer Treatment Market By Disease Indication
12.6.4 Latin America Stomach Cancer Treatment Market By Drug Class
12.6.5 Latin America Stomach Cancer Treatment Market By Distribution Channel
12.6.6 Brazil
12.6.6.1 Brazil Stomach Cancer Treatment Market by Treatment Type
12.6.6.2 Brazil Stomach Cancer Treatment Market By Disease Indication
12.6.6.3 Brazil Stomach Cancer Treatment Market By Drug Class
12.6.6.4 Brazil Stomach Cancer Treatment Market By Distribution Channel
12.6.7 Argentina
12.6.7.1 Argentina Stomach Cancer Treatment Market by Treatment Type
12.6.7.2 Argentina Stomach Cancer Treatment Market By Disease Indication
12.6.7.3 Argentina Stomach Cancer Treatment Market By Drug Class
12.6.7.4 Argentina Stomach Cancer Treatment Market By Distribution Channel
12.6.8 Colombia
12.6.8.1 Colombia Stomach Cancer Treatment Market by Treatment Type
12.6.8.2 Colombia Stomach Cancer Treatment Market By Disease Indication
12.6.8.3 Colombia Stomach Cancer Treatment Market By Drug Class
12.6.8.4 Colombia Stomach Cancer Treatment Market By Distribution Channel
12.6.9 Rest of Latin America
12.6.9.1 Rest of Latin America Stomach Cancer Treatment Market by Treatment Type
12.6.9.2 Rest of Latin America Stomach Cancer Treatment Market By Disease Indication
12.6.9.3 Rest of Latin America Stomach Cancer Treatment Market By Drug Class
12.6.9.4 Rest of Latin America Stomach Cancer Treatment Market By Distribution Channel
13 Company profile
13.1 Novartis AG.
13.1.1 Company Overview
13.1.2 Financials
13.1.3Product/Services/Offerings
13.1.4 SWOT Analysis
13.1.5 The SNS View
13.2 Pfizer, Inc.
13.2.1 Company Overview
13.2.2 Financials
13.2.3Product/Services/Offerings
13.2.4 SWOT Analysis
13.2.5 The SNS View
13.3 Mylan N.V.
13.3.1 Company Overview
13.3.2 Financials
13.3.3Product/Services/Offerings
13.3.4 SWOT Analysis
13.3.5 The SNS View
13.4 F. Hoffmann La Roche Ltd.
13.4.1 Company Overview
13.4.2 Financials
13.4.3Product/Services/Offerings
13.4.4 SWOT Analysis
13.4.5 The SNS View
13.5 Eli Lilly And Company.
13.5.1 Company Overview
13.5.2 Financials
13.5.3Product/Services/Offerings
13.5.4 SWOT Analysis
13.5.5 The SNS View
13.6 Merck & Co., Inc.
13.6.1 Company Overview
13.6.2 Financials
13.6.3Product/Services/Offerings
13.6.4 SWOT Analysis
13.6.5 The SNS View
13.7 Teva Pharmaceutical Industries Ltd.
13.7.1 Company Overview
13.7.2 Financials
13.7.3Product/Services/Offerings
13.7.4 SWOT Analysis
13.7.5 The SNS View
13.8 Celltrion Healthcare Co., Ltd.
13.8.1 Company Overview
13.8.2 Financial
13.8.3Product/Services/Offerings
13.8.4 SWOT Analysis
13.8.5 The SNS View
13.9 Samsung Bioepis.
13.9.1 Company Overview
13.9.2 Financials
13.9.3 Product/Service/Offerings
13.9.4 SWOT Analysis
13.9.5 The SNS View
13.10 Bristol Myers Squibb Company.
13.10.1 Company Overview
13.10.2 Financials
13.10.3 Product/Service/Offerings
13.10.4 SWOT Analysis
13.10.5 The SNS View
14. Competitive Landscape
14.1 Competitive Benchmarking
14.2 Company Share Analysis
14.3 Recent Developments
14.3.1 Industry News
14.3.2 Company News
14.3.3 Mergers & Acquisitions
15. USE Cases and Best Practices
16. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Inflammatory Bowel Disease Drugs Market size was valued at USD 21.15 Billion in 2023 and is expected to reach USD 27.65 Billion By 2031 and grow at a CAGR of 3.47% over the forecast period of 2024-2031.
The Cystic Fibrosis Market size was valued at US$ 7.13 Billion in 2022 and is estimated to reach US$ 39.59 Billion by 2030 with a growing CAGR of 23.9% Over the Forecast Period 2023-2030.
The Feminine Hygiene Products Market Size was valued at USD 24.5 billion in 2023 and is expected to reach USD 37.88 billion by 2031 and grow at a CAGR of 5.6% over the forecast period 2024-2031.
The Digital Radiology Rarket was estimated at USD 12.19 billion in 2022 and is projected to reach USD 22.40 billion by 2030, developing at a CAGR of 7.9% from 2023 to 2030.
Biopharmaceutical Excipients Market Size was Valued $2.7 billion in 2023 & is Expected to Reach $4.17 billion by 2031 & growing at a CAGR of 5.6% by 2024-2031
The Laboratory Information Management System (LIMS) Market Size was valued at USD 2.05 billion in 2022, and is expected to reach USD 3.69 billion by 2030 and grow at a CAGR of 7.6% over the forecast period 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
